Subcutaneous vs Intramuscular TRT Injections: What the Evidence Shows in 2026

What's the short answer?

The short answer: For subcutaneous vs intramuscular TRT, the published evidence shows both routes reach comparable therapeutic testosterone levels at similar weekly doses. Subcutaneous (subq) injection is less painful, uses a smaller needle, and may produce gentler peaks. Intramuscular (IM) is the traditional, FDA-labeled route for vialed testosterone cypionate. The needle location changes the depot tissue, not whether the testosterone works.

The differences most men care about — efficacy, estradiol, and hematocrit — are driven far more by your total weekly dose and injection frequency than by whether the needle enters muscle or fat. The biggest practical advantages of subq are comfort and convenience.

One regulatory detail matters: as of 2026, Xyosted (a testosterone enanthate auto-injector) is the only testosterone product the FDA has approved specifically for subcutaneous use. Injecting standard cypionate subq is common and evidence-backed, but technically off-label. The rest of this guide walks through what the studies actually show.

Side-by-side comparison

How does subcutaneous injection work?

Subcutaneous injection delivers testosterone into the layer of fat just beneath the skin — typically the abdomen (about two inches from the navel) or the upper thigh. The oil-based testosterone forms a depot in fatty tissue, which has less blood flow than muscle, so the ester releases into circulation gradually.

Because subq tissue absorbs the oil more slowly, the testosterone peak after a subq injection tends to be lower and broader than the spike seen after an IM dose. Many patients and prescribers consider this gentler curve a benefit, since sharp peaks are associated with more side-effect complaints.

Subq injections use insulin-style syringes or short pen needles — usually 27 to 31 gauge and 1/2 inch or shorter. The thin needle and shallow insertion are why most men describe subq as nearly painless compared with a deep glute shot.

Practical subq technique points

• Pinch the fat and insert at a 45 to 90 degree angle into the subcutaneous layer, not the muscle beneath.
• Keep volume low — splitting a weekly dose into two or three smaller injections improves comfort and absorption.
• Rotate sites between the abdomen and thighs to reduce local irritation.
• Expect occasional redness or itching at the site; persistent lumps or large reactions warrant a call to your prescriber.

How does intramuscular injection work?

Intramuscular injection delivers testosterone deep into muscle tissue — most commonly the ventrogluteal (hip), vastus lateralis (outer thigh), or deltoid (shoulder). Muscle is highly vascular, so the oil depot releases testosterone into the bloodstream relatively quickly, producing a higher early peak.

IM is the route printed on the label for standard vialed testosterone cypionate and enanthate, the most widely prescribed and most affordable TRT preparations in the US. Decades of clinical use stand behind it, and it remains the default at many clinics.

The tradeoff is the needle. IM injection requires a 22-25 gauge needle, 1 to 1.5 inches long, to reach muscle. That larger needle and deeper insertion are the main reasons some patients find IM uncomfortable or develop occasional post-injection soreness.

With testosterone cypionate's roughly 8-day half-life, IM levels peak about 24-48 hours after the shot and decline until the next dose. Twice-weekly IM dosing narrows that peak-trough swing considerably, which is why most modern protocols favor it over every-other-week schedules. Our TRT blood work schedule covers how draw timing changes by ester and route.

Is subcutaneous TRT as effective as intramuscular?

Yes — this is the most studied question, and the answer is consistent. Subcutaneous testosterone reaches therapeutic serum concentrations comparable to intramuscular injection at equivalent or similar weekly doses.

The clearest evidence comes from several sources:

1. Spratt et al., JCEM 2017 (PMID 28645211): A dose-finding study of weekly subcutaneous testosterone enanthate found it produced stable total testosterone in the mid-normal range across a range of doses, establishing subq as a viable therapeutic route.
2. The Xyosted pivotal program: The FDA approval of Xyosted (subcutaneous testosterone enanthate auto-injector) was based on trial data showing the large majority of treated men achieved an average testosterone concentration within the eugonadal (normal) range over the dosing interval.
3. Retrospective TRT cohorts: Multiple clinic-based comparisons of off-label subcutaneous cypionate versus intramuscular cypionate have reported no clinically meaningful difference in achieved testosterone levels, with high patient satisfaction on subq.

The takeaway: route does not determine whether TRT works. Total dose, ester, and frequency determine your achieved levels. If your IM protocol holds you in range, an equivalent subq protocol generally will too.

Does subcutaneous testosterone cause less estradiol?

This is one of the most debated claims in TRT forums, and the honest answer is that the evidence does not consistently support a meaningful route-based difference in estradiol.

Two competing theories circulate:

• The "fat aromatizes" theory: Because adipose tissue contains aromatase, some argue injecting into fat raises estradiol. In practice, the testosterone leaves the depot and circulates systemically before most aromatization occurs, so this local effect is small.
• The "gentler peaks" theory: Others argue the lower subq peak means less substrate for aromatization at any moment, nudging estradiol down. There is some mechanistic logic here, but comparative clinical data are not strong enough to call it a reliable benefit.

What the data do support: estradiol on TRT tracks most closely with total testosterone dose, peak levels, body fat, and individual aromatase activity. If your estradiol runs high, adjusting dose, splitting injections to lower peaks, and improving body composition move the needle far more than changing the injection route.

For the full picture on interpreting E2, see our guide on estradiol on TRT, and our deep dive on when an aromatase inhibitor is actually needed — which, for most well-dosed men, is rarely.

How do subq and IM compare on hematocrit?

Erythrocytosis — a rise in red blood cell concentration measured as hematocrit — is the most common dose-limiting side effect of TRT. The question is whether the subcutaneous route raises it less than IM.

The theory is reasonable: a higher testosterone peak provides a stronger stimulus for erythropoiesis, so the gentler subq curve might blunt hematocrit gains. Some clinical observations support smaller increases with smaller, more frequent dosing.

But the comparative evidence is limited and inconsistent, and the dominant driver of hematocrit is total weekly dose and peak testosterone — not route per se. Practically:

• Switching from a large weekly IM dose to smaller, more frequent subq injections may help, because you are lowering peaks.
• Switching route while keeping the same large single dose is unlikely to fix high hematocrit on its own.
• The Endocrine Society and AUA flag a hematocrit of 54% as the threshold for dose reduction, pause, or therapeutic phlebotomy regardless of route.

Monitoring is non-negotiable either way. See our full breakdown of hematocrit on TRT for the thresholds and management options.

Is Xyosted the only FDA-approved subcutaneous testosterone?

Yes. As of 2026, Xyosted (testosterone enanthate), approved by the FDA in 2018, is the only testosterone product specifically labeled for subcutaneous administration. It is delivered through a single-dose, disposable auto-injector dosed once weekly, with strengths intended for at-home self-injection.

Everything else is a nuance worth understanding:

• Vialed testosterone cypionate and enanthate are FDA-labeled for intramuscular use. Injecting them subcutaneously is off-label.
• Off-label subq cypionate is widespread in clinical practice and supported by published evidence — off-label does not mean unsafe or improper, it means the specific product label does not list that route.
• Xyosted carries an FDA boxed warning for increases in blood pressure, which can raise cardiovascular risk. Blood pressure should be controlled before starting and monitored during therapy.

Technique, needles, and pain

The needle is where subq and IM differ most in day-to-day experience. This is the single biggest reason men switch routes.

Subcutaneous

• Needle: 27-31 gauge, 1/2 inch or shorter — the same caliber diabetics use for insulin.
• Site: Abdominal or thigh fat; pinch and inject into the fat layer.
• Pain: Most describe it as a quick pinch or nothing at all. Mild redness or itching at the site is the most common complaint.
• Volume: Lower per shot is better tolerated; many split the weekly dose to keep each injection small.

Intramuscular

• Needle: 22-25 gauge, 1-1.5 inch to reach muscle.
• Site: Ventrogluteal, vastus lateralis, or deltoid.
• Pain: A deeper stick, with occasional post-injection soreness for a day or two.
• Volume: Muscle tolerates larger volumes, so a full weekly dose in one shot is feasible.

Here's a simple table idea worth picturing: a two-column "needle anxiety decision" layout where the left column lists reasons men avoid injections (fear of needles, pain, soreness) and the right column shows how subq addresses each one (insulin-thin needle, shallow stick, minimal soreness). For many men, that mapping is what makes self-injection feel doable.

Who should choose which?

Subcutaneous may be better if you:

• Have needle anxiety or dislike deep IM injections
• Want the simplest at-home self-injection routine
• Prefer smaller, more frequent doses for smoother levels
• Want an FDA-approved auto-injector option (Xyosted) and your blood pressure is well controlled
• Have experienced injection-site soreness or nodules with IM

Intramuscular may be better if you:

• Are already stable and satisfied on IM cypionate
• Prefer one injection per week or a larger single volume
• Want the lowest-cost, on-label vialed option
• Have very little subcutaneous fat for a reliable subq depot
• Have a prescriber who is most comfortable managing IM protocols

For most men, the choice comes down to comfort and habit rather than a clinical winner. Both routes can hold you in range with appropriate dosing and monitoring. If you are also weighing non-injection options, our comparisons of pellets vs injections and gel vs injections round out the full delivery-method picture, and HCG on TRT covers adjuncts that some men add for fertility.

The bottom line

Subcutaneous and intramuscular testosterone both work. The published evidence — from Spratt's 2017 dose-finding study through the Xyosted approval program and retrospective TRT cohorts — shows comparable achieved testosterone levels at similar weekly doses. The route changes the depot tissue and the needle, not the therapy.

Subcutaneous wins on comfort: a thin insulin-style needle, a shallow stick, and gentler peaks. Intramuscular wins on simplicity and being the on-label, lowest-cost route for vialed cypionate. The much-discussed estradiol and hematocrit advantages of subq are weak in the data — those numbers are driven by dose and frequency, not by where the needle goes.

Remember the one regulatory fact: Xyosted is the only FDA-approved subcutaneous testosterone; off-label subq cypionate is common and evidence-backed but still a prescriber-guided decision. Whichever route you choose, the fundamentals are unchanged — proper diagnosis, appropriate dosing, and regular blood work to confirm your testosterone, estradiol, and hematocrit are where they should be.